Titan’s Probuphine Gets Panel Endorsement, But With Many Caveats
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Psychopharmacologic Drugs Advisory Committee outlines multiple concerns with the implantable opioid dependence product, including REMS problems and a lack of sufficient dose-ranging studies.